{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"473"}]}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Non-Treatment emergent positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Treatment emergent positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"495"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Pre- and post-baseline serum samples from participants treated with pembrolizumab were analyzed for ADA by means of a neutralizing antibody assay which assessed the ability of ADA to block (neutralize) binding of pembrolizumab to Programmed Cell Death-1 (PD-1) protein. Overall immunogenicity was defined as the number of treatment emergent positive participants based on the total number of evaluable participants (treatment emergent positive, non-treatment emergent positive and negative immunogenicity status).","groups":[{"description":"In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.","id":"OG000","title":"Pembrolizumab"},{"description":"In Part 1, participants received placebo IV as post-surgery therapy Q3W.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants in Part 1 who had at least one ADA sample available after treatment with pembrolizumab and who had treatment emergent positive, non-treatment emergent positive, or negative immunogenicity status. Participants receiving Placebo treatment in Part 1 were not analyzed for ADA.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.","title":"Number of Participants Positive for Anti-Drug Antibodies (ADA) After Pembrolizumab Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}